Eplerenone Post-Ami Heart Failure Efficacy And Survival Study: Difference between revisions
No edit summary |
|||
Line 10: | Line 10: | ||
[[Eplerenone]] is an [[aldosterone antagonist]] that blocks the mineralocorticoid receptor. In contrast to [[spironolactone]], it does not block the glucocorticoid, progesterone, or androgen receptors and for that reason it may may be associated with fewer side effects than [[spironolactone]]. Pre clinical studies have demonstrated that aldosterone antagonism may improve ventricular remodeling and collagen formation among patients who sustain LV dysfunction following an MI. | [[Eplerenone]] is an [[aldosterone antagonist]] that blocks the mineralocorticoid receptor. In contrast to [[spironolactone]], it does not block the glucocorticoid, progesterone, or androgen receptors and for that reason it may may be associated with fewer side effects than [[spironolactone]]. Pre clinical studies have demonstrated that aldosterone antagonism may improve ventricular remodeling and collagen formation among patients who sustain LV dysfunction following an MI. | ||
The EPHESUS study builds upon the [[RALES]] study (Randomized Aldactone Evaluation Study) which demonstrated that aldosterone inhibition with the older agent [[spironolactone]] reduced mortality when added to an ACE inhibitor among patients with severe [[congestive heart failure]]. | The EPHESUS study builds upon the [[RALES]] study ([[Randomized Aldactone Evaluation Study]]) which demonstrated that aldosterone inhibition with the older agent [[spironolactone]] reduced mortality when added to an ACE inhibitor among patients with severe [[congestive heart failure]]. | ||
==Results== | ==Results== |
Revision as of 19:35, 4 October 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Acronym
EPHESUS stands for Eplerenone Post-AMI Heart Failure Efficacy and Survival Trial.
Background
Eplerenone is an aldosterone antagonist that blocks the mineralocorticoid receptor. In contrast to spironolactone, it does not block the glucocorticoid, progesterone, or androgen receptors and for that reason it may may be associated with fewer side effects than spironolactone. Pre clinical studies have demonstrated that aldosterone antagonism may improve ventricular remodeling and collagen formation among patients who sustain LV dysfunction following an MI.
The EPHESUS study builds upon the RALES study (Randomized Aldactone Evaluation Study) which demonstrated that aldosterone inhibition with the older agent spironolactone reduced mortality when added to an ACE inhibitor among patients with severe congestive heart failure.
Results
End point
|
Eplerenone, No. (%)
|
Placebo, No. (%)
|
Relative risk (95% CI)
|
p
|
Mortality* | 478 (14.4) | 554 (16.7) | 0.85 (0.75-0.96) |
0.008 |
Cardiovascular mortality | 407 (12.3) | 483 (14.6) | 0.83 (0.72-0.94) |
0.005 |
CV mortality or hospitalization for CV events* | 885 (26.7) | 993 (30.0) | 0.87 (0.79-0.95) |
0.002 |
*Primary end points
Number Needed to Treat (NNT) = 50 patients to save one life, and 33 to prevent one cardiovascular death or rehospitalization.
Summary
Among MI patients with LV dysfunction, the administration of eplerenone (Inspra®, Pharmacia) in addition to evidence based therapy is associated with a 15% reduction in all cause mortality. In addition, cardiovascular death, and CV death and hospitalization were also significantly reduced.